Compared to non-IBC, HER2+ IBC tumour cells engaged CD8+ T cells through the MIF–CD74 ligand–receptor axis, while CD8+ T cells specifically upregulated immune checkpoint molecules LAG3 and TIGIT. This evidence concerns the gene CD8A and neoplasm.